Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain EGRX message board posts where the ticker symbol EGRX has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest EGRX SEC Filings

Filings Format Description Filing Date File/Film Number
8-K  Documents Current report, items 8.01 and 9.01
Acc-no: 0001104659-18-044211 (34 Act)  Size: 42 KB
2018-07-09 001-36306
18943377
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-041189 Size: 7 KB
2018-07-03
8-K  Documents Current report, item 5.07
Acc-no: 0001104659-18-041821 (34 Act)  Size: 32 KB
2018-06-22 001-36306
18915129
8-K  Documents Current report, items 8.01 and 9.01
Acc-no: 0001104659-18-039299 (34 Act)  Size: 44 KB
2018-06-11 001-36306
18890931
8-K  Documents Current report, items 8.01 and 9.01
Acc-no: 0001104659-18-033632 (34 Act)  Size: 41 KB
2018-05-16 001-36306
18838766
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0000827871-18-000005 (34 Act)  Size: 5 MB
2018-05-10 001-36306
18823176
8-K  Documents Current report, items 2.02 and 9.01
Acc-no: 0001104659-18-031932 (34 Act)  Size: 315 KB
2018-05-10 001-36306
18820454
DEFA14A  Documents Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Acc-no: 0001104659-18-028560 (34 Act)  Size: 282 KB
2018-04-30 001-36306
18790067
DEF 14A  Documents Other definitive proxy statements
Acc-no: 0001047469-18-003351 (34 Act)  Size: 1 MB
2018-04-30 001-36306
18790037
8-K  Documents Current report, items 8.01 and 9.01
Acc-no: 0001104659-18-024064 (34 Act)  Size: 40 KB
2018-04-16 001-36306
18755533
More EGRX SEC Filings


Related news from
Thu, 12 Jul 2018
12:05:38 +0000
See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.
Eagle Pharmaceuticals Inc NASDAQ NMS:EGRX
Mon, 09 Jul 2018
11:00:00 +0000
FDA Grants Eagle Seven Year Orphan Drug Exclusivity for BENDEKA (bendamustine hydrochloride injection)
Eagle Pharmaceuticals, Inc. (EGRX) (“Eagle” or the “Company”) announced today that the U.S. Food and Drug Administration (FDA) has granted seven years of orphan drug exclusivity (ODE) in the U.S., for BENDEKA™ (bendamustine hydrochloride injection, or bendamustine HCI), a liquid, low-volume (50 mL) and short-time 10-minute infusion formulation of bendamustine hydrochloride. As a result, and consistent with the order issued by the U.S. District Court for the District of Columbia (the Court) on June 8, 2018, the FDA will not approve any drug applications referencing BENDEKA until the ODE expires in December 2022.
Tue, 03 Jul 2018
12:30:00 +0000
Eagle Pharmaceuticals Announces New Patent Issued for BENDEKA
-- BENDEKA protected by 15 patents running from 2026 through 2033 –
Fri, 29 Jun 2018
11:30:00 +0000
Investor Expectations to Drive Momentum within Education Realty Trust, Eagle Pharmaceuticals, Boingo Wireless, United Parcel Service, Marathon Petroleum, and Coherent — Discovering Underlying Factors of Influence
NEW YORK, June 29, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Education ...
Fri, 15 Jun 2018
14:32:18 +0000
Teva’s Key Drugs in Its Specialty Products Pipeline
Teva Pharmaceutical’s (TEVA) fremanezumab is a key product awaiting FDA approval. The drug is also under Phase 2 trials for the treatment of post-traumatic headache and a Phase 3 trial for the treatment of cluster headache. The drug is expected to generate significant sales for the company in the years ahead. Teva’s specialty products pipeline is shown in the chart below.
Mon, 11 Jun 2018
13:32:07 +0000
Benzinga Pro's 5 Stocks To Watch Today
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! NANO DIMENSION/S ADR (NASDAQ: NNDM ) stock was trading ...
Mon, 11 Jun 2018
12:05:40 +0000
Teva Stock Could Jump after Good News from Partner Manufacturers
Eagle Pharmaceuticals (EGRX), a US-based drug maker and a partner of Teva Pharmaceutical that specializes in the development of critical care drugs, won a lawsuit against the US FDA. The FDA had refused to grant orphan drug status to Teva Pharmaceutical and Eagle Pharmaceuticals’ Bendeka (bendamustine hydrochloride) for the treatment of individuals with chronic lymphocytic leukemia and indolent B-cell non-Hodgkin lymphoma. The orphan drug status will grant Teva Pharmaceutical an extra seven years of patent protection and market exclusivity.
Mon, 11 Jun 2018
10:50:00 +0000
Court Issues Decision in Favor of Eagle Pharmaceuticals Granting Seven Year Orphan Drug Exclusivity for BENDEKA (bendamustine hydrochloride injection)
Eagle Pharmaceuticals, Inc. (EGRX) (“Eagle” or the “Company”) announced today that the U.S. District Court for the District of Columbia (the Court) has issued a decision requiring the FDA to grant seven years of orphan drug exclusivity (ODE) in the U.S., for BENDEKA™ (bendamustine hydrochloride injection, or bendamustine HCI), a liquid, low-volume (50 mL) and short-time 10-minute infusion formulation of bendamustine hydrochloride. As a result of the Court’s decision, the FDA will not be able to approve any drug applications referencing BENDEKA until the ODE expires in December 2022.
Tue, 29 May 2018
20:30:00 +0000
Eagle Pharmaceuticals, Inc. to Present at Investor Conferences in June
Eagle Pharmaceuticals, Inc. announced today that management will present at two investor conferences in June as follows:
Fri, 18 May 2018
11:40:00 +0000
Wired News – FDA Granted Approval to Eagle Pharma’s Bendamustine Hydrochloride RTD Solution in a 500ml Admixture
LONDON, UK / ACCESSWIRE / May 18, 2018 / If you want access to our free research report on Eagle Pharma, Inc. (NASDAQ: EGRX) ("Eagle"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=EGRX as the Company's latest news hit the wire. On May 16, 2018, the Company announced that the US Food and Drug Administration (FDA) has granted final approval to the Company's ready-to-dilute (RTD) bendamustine hydrochloride (HCl) solution in a 500ml admixture for the treatment of patients with chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Active-Investors.com is currently working on the research report for Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX), which also belongs to the Healthcare sector as the Company Eagle Pharma.
Thu, 17 May 2018
11:50:00 +0000
Market Trends Toward New Normal in Agios Pharmaceuticals, Corcept Therapeutics, Prestige Brand, Virtu Financial, Eagle Pharmaceuticals, and Century Aluminum — Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, May 17, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Agios ...
Wed, 16 May 2018
10:50:00 +0000
Eagle Pharmaceuticals, Inc. Granted Final FDA Approval for Bendamustine Hydrochloride Ready-to-Dilute Solution in a 500ml Admixture
Eagle Pharmaceuticals, Inc. (“Eagle” or “the Company”) (EGRX) today announced that the U.S. Food and Drug Administration (FDA) has granted final approval for Eagle’s ready-to-dilute (RTD) bendamustine hydrochloride (HCl) solution in a 500ml admixture for the treatment of patients with chronic lymphocytic leukemia (CLL) and patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Eagle’s bendamustine HCl injection does not require reconstitution and is administered as a 500ml admixture over 30 or 60 minutes. Based upon our view of the market, we anticipate over time achieving up to a 12% market share, increasing our overall profitability,” stated Scott Tarriff, Chief Executive Officer of Eagle Pharmaceuticals.
Sun, 13 May 2018
09:46:36 +0000
Edited Transcript of EGRX earnings conference call or presentation 10-May-18 12:30pm GMT
Q1 2018 Eagle Pharmaceuticals Inc Earnings Call
Thu, 10 May 2018
11:11:32 +0000
Eagle Pharmaceuticals: 1Q Earnings Snapshot
On a per-share basis, the Woodcliff Lake, New Jersey-based company said it had profit of 17 cents. Earnings, adjusted for stock option expense and non-recurring costs, came to 53 cents per share. The specialty ...
Thu, 10 May 2018
10:50:00 +0000
Eagle Pharmaceuticals, Inc. Reports First Quarter 2018 Results
Eagle Pharmaceuticals, Inc. today announced its financial results for the three months ended March 31, 2018. Highlights of and subsequent
Wed, 02 May 2018
09:11:09 +0000
New Strong Sell Stocks for May 2nd
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Tue, 01 May 2018
20:30:00 +0000
Eagle Pharmaceuticals, Inc. to Discuss First Quarter 2018 Financial Results on May 10, 2018
Eagle Pharmaceuticals, Inc. today announced that the Company will release its 2018 first quarter financial results on Thursday, May 10, 2018, before the market opens.
Mon, 30 Apr 2018
20:30:00 +0000
Eagle Pharmaceuticals, Inc. to Present at 43rd Annual Deutsche Bank Health Care Conference
Eagle Pharmaceuticals, Inc. announced today that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the 43rd Annual Deu
Mon, 16 Apr 2018
11:00:00 +0000
Eagle Pharmaceuticals’ Vasopressin ANDA Accepted for Filing by the FDA
Eagle Pharmaceuticals, Inc. today announced that it has submitted and the U.S. Food and Drug Administration has accepted for filing its abbreviated new drug application for vasopressin injection, 1ml.



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "The collective wisdom of the members and distributed in an unselfish manner is what I find to be the most valuable asset of the group." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2018, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards